ABT-888，也称为Veliparib，是聚(ADP-核糖)聚合酶(PARP)抑制剂，并在与多种细胞毒性剂组合的广谱临床前肿瘤模型中显示出优异的体内功效。PARP参与DNA修复，PARP水平升高会导致对细胞毒性化疗和放疗的抗性。因此，PARP抑制剂有希望成为化疗和放射增敏剂。与微卫星稳定(MSS)细胞系(两种基因的野生型)相比，ABT-888对含有MRE11和RAD50基因突变的微卫星不稳定(MSI)细胞系也有活性。

产品性质：

Cas No.：912444-00-9

别名：维利帕尼; ABT-888

化学名： 1-[3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one

Canonical SMILES CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N

分子式：C13H16N4O

分子量：244.3

溶解度：≥ 6.1mg/mL in DMSO

储存条件：Store at -20°C

注意事项：

为了您的安全和健康，请穿实验服并戴一次性手套操作。

References：

1、Shivaani Kummar, Robert Kinders, Martin E. Gutierrez, Larry Rubinstein, Ralph E. Parchment, Lawrence R. Phillips, Jiuping Ji, Anne Monks, Jennifer A. Low, Alice Chen, Anthony J. Murgo, Jerry Collins, Seth M. Steinberg, Helen Eliopoulos, Vincent L. Giranda, Gary Gordon, Lee Helman, Robert Wiltrout, Joseph E. Tomaszewski and James H. Doroshow. Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies. Journal of Clinical Oncology. 2009; 27(16): 2705 – 11.

2、Xiaofeng Li, Juergen Delzer, Richard Voorman, Sonia M. de Morais and Yanbin Lao. Disposition and Drug-Drug Interaction Potential of Veliparib (ABT-888), a Novel and Potent Inhibitor of Poly (ADP-ribose) Polymerase. DRUG METABOLISM AND DISPOSITION. 2011; 39(7): 1161 – 69.

3、E. Vilar Sanchez, A. Chow, L. Raskin, M. D. Iniesta, B. Mukherjee and S. B. Gruber. Preclinical testing of the PARP inhibitor ABT-888 in microsatellite instable colorectal cancer. Journal of Clinical Oncology. 2009; 27(15S): 11028A.